REGN34 Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for REGN34 from our risk checks.
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$78.39 |
| 52 Week High | US$81.52 |
| 52 Week Low | US$55.99 |
| Beta | 0.14 |
| 1 Month Change | -2.00% |
| 3 Month Change | 1.75% |
| 1 Year Change | 19.90% |
| 3 Year Change | 80.03% |
| 5 Year Change | n/a |
| Change since IPO | 278.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| REGN34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | -0.4% | 0.6% | -0.2% |
| 1Y | 19.9% | -5.0% | 13.7% |
Return vs Industry: REGN34 exceeded the BR Biotechs industry which returned -4.9% over the past year.
Return vs Market: REGN34 exceeded the BR Market which returned 13.9% over the past year.
Price Volatility
| REGN34 volatility | |
|---|---|
| REGN34 Average Weekly Movement | 3.2% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.8% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: REGN34 has not had significant price volatility in the past 3 months.
Volatility Over Time: REGN34's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 13,450 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
| REGN34 fundamental statistics | |
|---|---|
| Market cap | R$503.05b |
| Earnings (TTM) | R$20.42b |
| Revenue (TTM) | R$67.73b |
24.2x
P/E Ratio7.3x
P/S RatioIs REGN34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REGN34 income statement (TTM) | |
|---|---|
| Revenue | US$13.12b |
| Cost of Revenue | US$6.25b |
| Gross Profit | US$6.86b |
| Other Expenses | US$2.91b |
| Earnings | US$3.95b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 36.79 |
| Gross Margin | 52.32% |
| Net Profit Margin | 30.14% |
| Debt/Equity Ratio | 7.6% |
How did REGN34 perform over the long term?
See historical performance and comparison